120 related articles for article (PubMed ID: 8295009)
1. Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity.
Shattuck LA; Eshima D; Taylor AT; Anderson TL; Graham DL; Latino FA; Payne SE
J Nucl Med; 1994 Feb; 35(2):349-55. PubMed ID: 8295009
[TBL] [Abstract][Full Text] [Related]
2. Effects of generator eluate age on the radiochemical purity of fractionated 99Tcm-MAG3.
Hung JC; Thorson LM
Nucl Med Commun; 1995 Mar; 16(3):157-60. PubMed ID: 7770239
[TBL] [Abstract][Full Text] [Related]
3. Comparison of technetium-99m MAG3 kit with HPLC-purified technetium-99m MAG3 and OIH in rats.
Coveney JR; Robbins MS
J Nucl Med; 1987 Dec; 28(12):1881-7. PubMed ID: 2960790
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting the hepatobiliary excretion of 99mTc-MAG3: its clinical significance in routine renography.
Arroyo AJ; Semaan HB; Minkus KD; Patel YP
J Nucl Med Technol; 2003 Mar; 31(1):18-20. PubMed ID: 12624122
[TBL] [Abstract][Full Text] [Related]
5. An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.
Millar AM; O'Brien LM
Eur J Nucl Med; 1990; 16(8-10):615-9. PubMed ID: 2143474
[TBL] [Abstract][Full Text] [Related]
6. Preparation of 99Tcm-MAG3: no confirmation that sodium chloride injections from plastic containers affect radiochemical purity.
Millar AM; O'Brien LM
Nucl Med Commun; 1998 May; 19(5):475-7. PubMed ID: 9853337
[TBL] [Abstract][Full Text] [Related]
7. Testing different storage conditions for (99m)Tc-MAG3 kit: can hot fractioning reduce the cost per unit dose?
Kiratli PO; Salanci BV
J Nucl Med Technol; 2003 Jun; 31(2):74-5. PubMed ID: 12777456
[TBL] [Abstract][Full Text] [Related]
8. Quality control of instant kit 99mTc-mercapto acetyl triglycine with inter- and intra-operator measurements.
Bozkurt MF; Kiratli PO; Konyali D; Metin F
Hell J Nucl Med; 2009; 12(1):59-62. PubMed ID: 19330186
[TBL] [Abstract][Full Text] [Related]
9. [A comparison on radiochemical behavior and biological property of antisense oligonucleotide labeled with technetium-99m by two methods: NHS-MAG3 versus SHNHP].
Li Y; Tan T; Zheng J; Zhang C
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Aug; 25(4):889-93, 902. PubMed ID: 18788302
[TBL] [Abstract][Full Text] [Related]
10. [99mTc-generator eluates: effects on the radiochemical purity of the labelling products].
Schomäcker K; Gerad H; Gabruk-Szostak B; Schicha H; Malja S
Nuklearmedizin; 1994 Feb; 33(1):33-9. PubMed ID: 8134284
[TBL] [Abstract][Full Text] [Related]
11. Preparation of 99m Tc-MAG3: the effect on radiochemical purity of using sodium chloride injection from plastic ampoules that have been exposed to light.
Beattie LA; O'Brien LM; Waight CC; Homer NZ; Andrew R; Millar AM
Nucl Med Commun; 2008 Jul; 29(7):649-53. PubMed ID: 18528188
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.
Brandau W; Bubeck B; Eisenhut M; Taylor DM
Int J Rad Appl Instrum A; 1988; 39(2):121-9. PubMed ID: 2833469
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors.
Liu M; Wang RF; Zhang CL; Yan P; Yu MM; Di LJ; Liu HJ; Guo FQ
J Nucl Med; 2007 Dec; 48(12):2028-36. PubMed ID: 18006621
[TBL] [Abstract][Full Text] [Related]
14. 99Tcm-MAG3: in vitro stability and in vivo behaviour at different times after preparation.
Millar AM; Wilkinson AG; McAteer E; Best JJ
Nucl Med Commun; 1990 Jun; 11(6):405-12. PubMed ID: 2143569
[TBL] [Abstract][Full Text] [Related]
15. Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells.
Zhang YR; Zhang YX; Cao W; Lan XL
J Nucl Med; 2005 Jun; 46(6):1052-8. PubMed ID: 15937319
[TBL] [Abstract][Full Text] [Related]
16. Anomalies in hepatobiliary excretion of technetium-99m-MAG3 preparations.
Chatterjee M; Majumder A; Iyer P; Muthukrishnan G; Das MK; Ramamoorthy N; Desai CN; Banerjee S
Nucl Med Biol; 1996 Oct; 23(7):867-72. PubMed ID: 8971853
[TBL] [Abstract][Full Text] [Related]
17. Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure.
Taylor A; Eshima D; Christian PE; Wooten WW; Hansen L; McElvany K
J Nucl Med; 1988 May; 29(5):616-22. PubMed ID: 2967353
[TBL] [Abstract][Full Text] [Related]
18. A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine.
Chen F; Decristoforo C; Rohrbacher B; Riccabona G
Eur J Nucl Med; 1993 Apr; 20(4):334-8. PubMed ID: 8491226
[TBL] [Abstract][Full Text] [Related]
19. Kit preparation of technetium-99m-mercaptoacetyltriglycine: analysis, biodistribution and comparison with technetium-99m-DTPA in patients with impaired renal function.
Bannister KM; Penglis S; Bellen JC; Baker RJ; Chatterton BE
J Nucl Med; 1990 Sep; 31(9):1568-73. PubMed ID: 2144317
[TBL] [Abstract][Full Text] [Related]
20. Effect of source and age of sodium pertechnetate Tc 99m on radiochemical purity of technetium Tc 99m exametazime.
Millar AM
Am J Hosp Pharm; 1993 Jan; 50(1):103-6. PubMed ID: 8381258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
